Novel antineoplastics targeting genetic changes in colorectal cancer

Jamal Joudeh, Joshua E. Allen, Avisnata Das, Varun Prabhu, Michael Farbaniec, Jeffrey Adler, Wafik S. El-Deiry

Research output: Chapter in Book/Report/Conference proceedingChapter

4 Scopus citations


Cytotoxic chemotherapy remains the mainstay of the medical management of colorectal cancer (CRC). Research over the last two decades has led to a molecular understanding of the oncogenic mechanisms involved in CRC and has contributed to the rational development of antineoplastics that target these mechanisms. During carcinogenesis, genetic changes often occur in molecules that play key functional roles in cancer such as cell proliferation, angiogenesis, apoptosis, cell death and immune-mediated destruction of cancer cells. Here, we review novel antineoplastics that are approved or in development for CRC that target molecules associated with genetic aberrations in CRC. Some of these targeted antineoplastics have proven effective against other solid tumors and hold promise in treating CRC whereas others are now routinely used in combination with cytotoxic agents. This article reviews antineoplastics that target genetic changes in CRC, their antitumor mechanisms, and their stage of development.

Original languageEnglish (US)
Title of host publicationImpact of Genetic Targets on Cancer Therapy
PublisherSpringer Science and Business Media, LLC
Number of pages34
ISBN (Print)9781461461753
StatePublished - 2013

Publication series

NameAdvances in Experimental Medicine and Biology
ISSN (Print)0065-2598

All Science Journal Classification (ASJC) codes

  • General Biochemistry, Genetics and Molecular Biology


Dive into the research topics of 'Novel antineoplastics targeting genetic changes in colorectal cancer'. Together they form a unique fingerprint.

Cite this